Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older who are able and willing to give informed consent to participate
• People who have a type of lymphoma (a blood cancer) that has come back or stopped responding to treatment, have already received at least 2 different rounds of treatment, and are not suitable for other treatments that could potentially cure the cancer
• People who have recovered from serious side effects of previous cancer treatments (hair loss is an exception)
• People with a confirmed diagnosis of a specific type of non-Hodgkin lymphoma (NHL) — the trial site can confirm which specific subtypes are eligible, as some types are eligible for one treatment approach and others for a combination approach
• People who have at least one accessible tumour site (a lymph node or skin/tissue lump measuring 1.5 to 5 cm) that a specialist doctor determines is safe to inject into, and which has not previously been treated with radiation
• People with a life expectancy of more than 3 months, confirmed within 7 days before starting treatment
• People who are reasonably physically active and able to carry out daily activities with minimal limitations, as assessed using a standard medical scale (confirm with trial site)
• People whose blood test results show adequate levels of red blood cells, white blood cells, and platelets, confirmed within 7 days before starting treatment
• People with adequate liver and kidney function, confirmed within 7 days before starting treatment
• People with good heart function, classified as the least severe category on a standard heart health scale, confirmed within 7 days before starting treatment
• People who are not pregnant, not planning to become pregnant, and have a negative pregnancy test result within 72 hours before starting treatment (where applicable)
• People of reproductive potential who agree to use an effective form of contraception during the trial and for at least 90 days after treatment ends — specific acceptable methods apply for both biologically female and biologically male participants (confirm with trial site)
• People who, in the investigator's opinion, are willing and able to follow all study procedures, including injections into the tumour, scheduled visits, biopsies, and follow-up appointments

Who may not be able to join:

• People who have previously received a type of therapy involving direct injection into a tumour (ITI therapy)
• People who have had an autologous stem cell transplant or CAR-T cell therapy within the past month, or an allogeneic (donor) stem cell transplant within the past 6 months, or who are still experiencing graft-versus-host disease or taking medication to suppress it
• People who have received systemic cancer treatment within the past 14 days before starting the study treatment
• People who have received a specific immune-stimulating therapy called IL-2 within the past 6 months
• People with HIV or other acquired immune system deficiencies
• People with uncontrolled high blood pressure (above 180/100 mmHg)
• People diagnosed with a specific subtype called "unclassifiable B cell lymphoma"
• People with blood clotting problems or abnormal results on blood clotting tests
• People currently taking blood-thinning or anti-platelet medications that could increase the risk of complications from tumour injections
• People with significant lung disease that, in the investigator's opinion, could make them unable to tolerate certain side effects of treatment
• People with known alcohol or drug abuse
• People who have taken part in another clinical trial and received an experimental treatment within the past 30 days
• People who require ongoing steroid medication (such as prednisone at 10 mg per day or more) or other medications that suppress the immune system
• People with active cancer that has spread to the brain or central nervous system
• People who are not suitable to receive a specific type of focused radiation therapy, as determined by the radiation specialist and principal investigator (applies to certain treatment groups only)
• People with active, uncontrolled hepatitis B, C, or D infection
• People who have received a live vaccine within 4 weeks before the screening visit
• People with active or uncontrolled autoimmune disease, or a history of autoimmune disease considered at high risk of returning
• People with another active cancer, or any other serious medical, psychiatric, or personal circumstance that the investigator believes could interfere with safely completing the study
• People with an active systemic infection at the time treatment is due to begin

Important: Always verify eligibility with the trial site directly before applying.